Clinical practice guidelines are omnipresent and increasing in
number; however, their utility and applicability are questioned.
A great deal of effort is expended in their creation, but how they
reach their ultimate customers is very variable. The pharmaceutical
industry has considerable resources that may assist in this process;
however, they need to be more involved in the development of clinical
practice guidelines. This can happen only if both guideline developers
and industry set aside their fears, concerns, and prejudices and
collectively try to improve health care through more appropriate
management of patients.